Cellerys
Cellerys AG is a pre-revenue, clinical-stage Swiss biotech developing CLS12311, an autologous red blood cell-based immune tolerance therapy for relapsing remitting multiple sclerosis, currently advancing through the RED4MS Phase Ib/IIa trial in Europe.
- Company typePrivate
- Founded2015
- HeadquartersZürich, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellerys does
Cellerys AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinoff from the University of Zurich, developing CLS12311, an autologous cell therapy designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS). The therapy works by collecting a patient's own red blood cells, chemically coupling them ex vivo with twelve peptides representing the major target antigens in MS, and reinfusing them; the coupled cells then undergo natural apoptosis and are presented in a tolerogenic fashion in the liver and spleen, re-establishing immune tolerance without broadly suppressing the immune system. The product is being evaluated in the RED4MS Phase Ib/IIa trial across four European countries, with Phase Ib enrollment completed in December 2025 and Phase IIa preparation underway.
The company is pre-revenue and operates as a single-asset biotech with no disclosed pricing, licensing milestones, or commercial product. Its go-to-market model is the standard clinical-stage biotech pathway: advancing CLS12311 through regulated clinical trials with the goal of a future out-licensing, partnership, or trade sale. The company is headquartered in Schlieren (Zurich) with 11-50 employees, and is led scientifically by co-founders Roland Martin (CSO), Mireia Sospedra (Senior Principal Scientist), and Andreas Lutterotti (CMO), with Claudia Mitchell as Board Chair. Novartis holds a purchase option obtained through a June 2021 partnership that funded the Phase Ib program, and Wyss Zurich (a University of Zurich/ETH Zurich accelerator) provided early support. There are no disclosed venture capital rounds, institutional equity raises, or product revenue.
Cellerys firmographics
Firmographics- Name
- Cellerys
- Legal name
- Cellerys AG
- Website
- https://cellerys.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cellerys AG is a pre-revenue, clinical-stage Swiss biotech developing CLS12311, an autologous red blood cell-based immune tolerance therapy for relapsing remitting multiple sclerosis, currently advancing through the RED4MS Phase Ib/IIa trial in Europe.
- Ownership category
- akta.pro rank
Cellerys industry classification
Industry- Product category
- Multiple Sclerosis Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Multiple Sclerosis & Neuroimmunology (HLAKAIAF)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Cellerys is headquartered
LocationHeadquarters
- HQ city
- Zürich
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Cellerys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CLS12311 Commercialization: Pre-revenue clinical-stage biotech company developing an immune tolerance therapy for multiple sclerosis. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of CLS12311.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Cellerys product offering
Product offeringCore offering
Cellerys is developing CLS12311, a clinical-stage autologous cell therapy for relapsing remitting multiple sclerosis in which a patient's red blood cells are collected, chemically coupled ex vivo with twelve peptides representing the major target antigens in MS, and reinfused to re-establish antigen-specific immune tolerance. The therapy is being evaluated in the RED4MS Phase Ib/IIa clinical trial across four European countries, with the Phase Ib last-patient visit completed in December 2025.
Product overview
Cellerys is developing a single therapeutic product pipeline focused on immune tolerance induction for autoimmune diseases, specifically multiple sclerosis. The core product is CLS12311, a peptide-coupled red blood cell therapy where a patient's own RBCs are collected, coupled with specific peptides from target proteins associated with MS, and reinfused to restore immune tolerance. The RED4MS clinical trial is the development program for this therapy.
Differentiator
Problem solved
Functional benefit
Products and services
- CLS12311 Autologous red blood cells chemically coupled ex vivo with twelve peptides representing the major target antigens in multiple sclerosis, designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS) while leaving normal protective immune functions intact.
Companies that use Cellerys
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Cellerys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Cellerys partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Clinical Trial Sites (4 European Countries)majorRED4MS Phase IB/IIA clinical study is conducted in 4 countries across Europe. Multiple clinical investigators and collaborators provide outstanding support for the first-in-human trial.
Scale indicators3 records
Recent moves9 records
Expansion highlights5 records
Cellerys competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Cellerys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellerys leadership team
Management profileNumber of profiles
Profiles9 records
Cellerys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellerys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellerys
What does Cellerys do?
Cellerys is developing CLS12311, a clinical-stage autologous cell therapy for relapsing remitting multiple sclerosis in which a patient's red blood cells are collected, chemically coupled ex vivo with twelve peptides representing the major target antigens in MS, and reinfused to re-establish antigen-specific immune tolerance. The therapy is being evaluated in the RED4MS Phase Ib/IIa clinical trial across four European countries, with the Phase Ib last-patient visit completed in December 2025.
Is Cellerys a public or private company?
Cellerys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cellerys founded?
Cellerys was founded in 2015. It employs 11 to 50 people.
Where is Cellerys based?
Cellerys is headquartered in Zürich, Switzerland, in the Europe region.
How does Cellerys make money?
One revenue line is on record: CLS12311 Commercialization.
Does Cellerys have an API?
No public API is recorded for Cellerys.
What industry is Cellerys in?
Cellerys's product category is Multiple Sclerosis Therapy. Its primary akta.pro industry code is HLAKAIAF, Multiple Sclerosis & Neuroimmunology, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.